Erythropoietin Receptor (EPOR) (N-Term) Peptid
EPOR
Reaktivität: Maus
Wirt: Synthetic
BP, WB
-
- Target Alle EPOR Produkte
- EPOR (Erythropoietin Receptor (EPOR))
- Protein Region
- N-Term
- Spezies
- Maus
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Sequenz
- SVRFWCSLPT ADTSSFVPLE LQVTEASGSP RYHRIIHINE VVLLDAPAGL
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-Epor Antibody,. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Aufreinigung
- Purified
-
-
- Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Konzentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- EPOR (Erythropoietin Receptor (EPOR))
- Synonyme
- EPOR Peptide, epor Peptide, EPO-R Peptide, erythropoietin receptor Peptide, erythropoietin receptor L homeolog Peptide, EPOR Peptide, epor Peptide, Epor Peptide, epor.L Peptide
- Hintergrund
-
Epor is a receptor for erythropoietin. Epor mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, Epor can also activate STAT1 and STAT3. Epor may also activate the LYN tyrosine kinase.
Alias Symbols: -
Protein Interaction Partner: Crkl,Jak2,Kit,Lyn,Lyn,Pik3r1,Ptpn1,Stat5a,Stat5b
Protein Size: 507 - Molekulargewicht
- 55 kDa
- Gen-ID
- 13857
- NCBI Accession
- NM_010149, NP_034279
- UniProt
- P14753
-
Sie sind hier:
